As the frequency of CD20 expression in CD4+ T cells is relatively low, and HIV infection upregulates CD20, we wondered if reactivation of the latent reservoir might also upregulate CD20 in HIV-infected cells and render cells susceptible to Rituximab. The gene discussed is CD4; the disease is HIV infectious disease.